• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Heat Biologics, Inc. (Amendment)

    12/16/21 7:52:43 AM ET
    $HTBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HTBX alert in real time by email
    SC 13D/A 1 wolf_sc13da.htm SC 13D/A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

     

    HEAT BIOLOGICS, INC.

    (Name of Issuer)

     

    Common Stock, Par Value $0.0002 Per Share

    (Title of Class of Securities)

     

    42237K 409

    (CUSIP Number)

     

    Mr. Jeffrey Wolf

    Orion Holdings V, LLC

    Seed-One IV, LLC

    c/o Heat Biologics, Inc.

    627 Davis Drive

    Morrisville, North Carolina 27560

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    December 13, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]

     

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

    (Continued on following pages)

     

    (Page 1 of 8 pages)

    ———————

    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    CUSIP No. 42237K 409                                              13D                                              Page 2 of 8 pages

     

     

               

    1

     

     

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Jeffrey Wolf

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (a)    
      (b)    
      Not Applicable

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    SOURCE OF FUNDS

     

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
           
      Not Applicable

    6

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

                                   

    NUMBER OF

    7

    SOLE VOTING POWER

     

    1,708,023

    SHARES

    BENEFICIALLY

    OWNED BY

    8

    SHARED VOTING POWER

     

    21,255

    EACH

    REPORTING

    PERSON

    9

    SOLE DISPOSITIVE POWER

     

    1,708,023

    WITH

     

     

    10

    SHARED DISPOSITIVE POWER

     

    21,256

    11

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,729,279

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
        ✓  
       

    13

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.6%

    14

     

     

    TYPE OF REPORTING PERSON

     

    IN

     

    This filing of Amendment No. 6 to Schedule 13D is being made as a result of Mr. Wolf’s receipt of 246,305 shares of restricted shares of Common Stock and options to purchase 393,761 shares of Common Stock as compensation pursuant to the Company’s equity incentive plan on December 13, 2021. Based on 25,403,519 shares of common stock, par value $0.0002 per share (the “Common Stock”), of Heat Biologics, Inc., a Delaware corporation (the “Company”), outstanding as of December 13, 2021. Mr. Wolf held: (i) 1,094,045 shares of Common Stock directly; and (ii) options and restricted stock units to purchase an aggregate of 635,234 shares that are vested and currently exercisable or exercisable within 60 days of the date hereof and are included in the beneficial ownership of Mr. Wolf. In addition, Orion Holdings V, LLC, a Delaware limited liability company (“Orion”), held 11,025 shares of Common Stock and Seed-One Holdings VI, LLC, a Delaware limited liability company (“Seed-One”), held 10,231 shares of Common Stock. Mr. Wolf serves as the managing member of both Orion and Seed-One. Mr. Wolf is deemed to beneficially own the shares held by such entities as in his role as the managing member he has the control over the voting and disposition of any shares held by these entities.

     

    These shares of Common Stock do not include 3,781 shares of Common Stock beneficially owned by Mr. Wolf’s children’s trust, of which Mr. Wolf is not the trustee. Mr. Wolf disclaims beneficial ownership of these shares except to the extent of any pecuniary interest (as defined in Rule 16a–1(a)(2) promulgated under the Securities Exchange Act of 1934, as amended (the “Act”)) that he may have in such entities. Also, does not include options to purchase Common Stock that do not vest within 60 days of the date of this filing.

     

    In addition, if the market capitalization of the Company is in excess of $500 million for at least fifteen consecutive trading days, then Mr. Wolf will be entitled to receive additional restricted stock or a stock option equal to 2% of the then outstanding shares of Common Stock. Mr. Wolf possesses the sole power to vote and the sole power to direct the disposition of all securities of the Company beneficially owned by him, Orion and Seed-One.  As a result of the foregoing, as of the filing date of this Amendment No. 6, Mr. Wolf is deemed to beneficially own an aggregate of 1,729,279 shares of Common Stock, or 6.6% of the outstanding shares of Common Stock.

     

     
     

     

    CUSIP No. 42237K 409                                              13D                                          Page 3 of 8 pages

     

     

               

    1

     

     

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Orion Holdings V, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (a)    
      (b)    
      Not Applicable

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    SOURCE OF FUNDS

     

    PF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
           
      Not Applicable

    6

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

                                   

    NUMBER OF

    7

    SOLE VOTING POWER

     

    0*

    SHARES

    BENEFICIALLY

    OWNED BY

    8

    SHARED VOTING POWER

     

    11,025*

    EACH

    REPORTING

    PERSON

    9

    SOLE DISPOSITIVE POWER

     

    0*

    WITH

     

     

    10

    SHARED DISPOSITIVE POWER

     

    11,025*

    11

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,025*

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
           
       

    13

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Less than 1%*

    14

     

     

    TYPE OF REPORTING PERSON

     

    OO (Limited Liability Company)

     

    *Based on 25,403,519 shares of Common Stock outstanding as of December 13, 2021.  As of the filing date of this Amendment No. 6, Orion is deemed to beneficially own 11,025 shares of Common Stock, or less than 1% of the outstanding shares of Common Stock.

     

     
     

     

    CUSIP No. 42237K 409                                              13D                                              Page 4 of 8 pages

     

               

    1

     

     

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Seed-One Holdings VI, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (a)    
      (b)    
      Not Applicable

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    SOURCE OF FUNDS

     

    PF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
           
      Not Applicable

    6

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

                                   

    NUMBER OF

    7

    SOLE VOTING POWER

     

    0*

    SHARES

    BENEFICIALLY

    OWNED BY

    8

    SHARED VOTING POWER

     

    10,231*

    EACH

    REPORTING

    PERSON

    9

    SOLE DISPOSITIVE POWER

     

    0*

    WITH

     

     

    10

    SHARED DISPOSITIVE POWER

     

    10,231*

    11

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,231*

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
           
       

    13

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Less than 1% *

    14

     

     

    TYPE OF REPORTING PERSON

     

    OO (Limited Liability Company)

     

    *Based on 25,403,519 shares of Common Stock outstanding as of December 13, 2021.  As of the filing date of this Amendment No. 6, Seed-One held 10,231 shares of Common Stock.  Or less than 1%of the outstanding shares of Common Stock.

     

     

     

     
     

     

    CUSIP No. 42237K 409                                              13D                               Page 5 of 8 pages

     

    Item 1. Security and Issuer.

     

    This Amendment No. 6 (this “Amendment No. 6”) amends the Schedule 13D, dated July 29, 2013 (the “Original 13D”), Amendment No. 1 to the Original 13D, dated February 9, 2017 (“Amendment No. 1”), Amendment No. 2 to the Original 13D, dated March 7, 2017 (“Amendment No. 2”), Amendment No. 3 to the Original 13D, dated April 27, 2017 (“Amendment No. 3”), Amendment No. 4 to the Original 13 D, dated January 2, 2020 (“Amendment No. 4”), and Amendment No. 5 to the Original 13D, dated January 4, 2021 (“Amendment No. 5”) , each filed by Mr. Wolf, Orion, and Seed-One.  Mr. Wolf, Orion and Seed-One are collectively referred to as the “Reporting Persons”). Capitalized terms not defined herein shall have the respective meanings ascribed to them in the Original 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, or Amendment No. 4 or Amendment No. 5

     

    The class of equity securities to which this Amendment No. 6 relates is the Common Stock, of Heat Biologics, Inc., a Delaware corporation (the “Company”).  The principal executive offices of the Company are located at 627 Davis Drive, Morrisville, North Carolina 27560.

     

    Item 2. Identity and Background.

     

    Item 2 is hereby amended and supplemented as follows:

     

    Mr. Wolf is the managing member of Orion and Seed-One. The address of the principal business office of Mr. Wolf and each of Orion and Seed-One is c/o Heat Biologics, Inc., 627 Davis Drive Morrisville, North Carolina 27560. The present principal occupation of Mr. Wolf is President and Chief Executive Officer of the Company.

     

    During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors), or been a party to any civil proceeding commenced before a judicial or administrative body of competent jurisdiction as a result of which the Reporting Persons was or is now subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Mr. Wolf is a citizen of the United States of America. Orion and Seed-One are each a limited liability company organized under the laws of the State of Delaware.

     

    Item 3. Source or Amount of Funds or Other Consideration.

     

    Item 3 is hereby amended and supplemented by adding the following:

     

    As described more fully under Item 5 below, Mr. Wolf received 246,305 shares of restricted Common Stock and options to purchase 393,761 shares of Common Stock as compensation on December 13, 2021.

     

    Item 4. Purpose of the Transaction.

     

    Item 4 is hereby amended and supplemented by adding the following:

     

    This filing of Amendment No. 6 to Schedule 13D is being made as a result of Mr. Wolf’s receipt of 246,305 shares of restricted Common Stock and options to purchase 393,761 shares of Common Stock as compensation on December 13, 2021 pursuant to the Company’s equity incentive plan. The shares of restricted Common Stock vest as follows: 50% vest immediately, and the remaining 50% vest and are no longer subject to forfeiture on January 1, 2022, subject to Mr. Wolf’s continuous service to the Company on each applicable vesting date. The restricted Common Stock was issued pursuant to the terms of an amended and restated restricted stock agreement that was entered into between the Company and Mr. Wolf, the form of which is incorporated by reference hereto and attached hereto as Exhibit 2. The amended and restated restricted stock agreement provides that sales or transfers made after the grant date are subject to the right of the Company to buy back the stock at any time that the holder desires to sell the restricted stock at a price equal to the lower of the closing price per share and 10 times the closing price per share on the date of grant.

     

     
     

     

    CUSIP No. 42237K 409                                              13D                                              Page 6 of 8 pages

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 is hereby amended and restated in its entirety as follows:

     

    As of the date hereof, the aggregate number and percentage of shares of Common Stock deemed beneficially owned by the Reporting Persons (based on 25,403,519 shares of Common Stock outstanding as of December 13, 2021, including the restricted shares of Common Stock issued as compensation to Mr. Wolf in December 2021) are as follows:

     

    (a)   shares of Common Stock deemed beneficially owned:  Percent of class of  shares of Common Stock:
      (i) Mr. Wolf: 1,708,023* 6.6%
      (ii) Orion: 11,025* Less than 1%
      (iii) Seed-One: 10,231* Less than 1%
         
    (b) Number of  shares of Common Stock as to which Mr. Wolf has:  
      (i) Sole power to vote or to direct the vote: 1,708,023*  
      (ii) Shared power to vote or to direct the vote:  21,256*  
      (iii) Sole power to dispose or to direct the disposition of:  1,708,023*  
      (iv) Shared power to dispose or to direct the disposition of:  21,256*  
         
      Number of  shares of Common Stock as to which Orion has:  
      (i) Sole power to vote or to direct the vote:  0*  
      (ii) Shared power to vote or to direct the vote:  11,025*  
      (iii) Sole power to dispose or to direct the disposition of:  0*  
      (iv) Shared power to dispose or to direct the disposition of:  11,025*  
         
      Number of  shares of Common Stock as to which Seed-One has:  
      (i) Sole power to vote or to direct the vote:  0*  
      (ii) Shared power to vote or to direct the vote:  10,231*  
      (iii)  Sole power to dispose or to direct the disposition of:  0*  
      (iv)  Shared power to dispose or to direct the disposition of:  10,231*  

    ———————

    *Based on 25,403,519 shares of Common Stock outstanding as of December 13, 2021. Does not include 3,781 Common Shares beneficially owned by Mr. Wolf’s children’s trust, of which Mr. Wolf is not the trustee. Mr. Wolf disclaims beneficial ownership of these shares except to the extent of any pecuniary interest (as defined in Rule 16a–1(a)(2) promulgated under the Act) that he may have in such entities. In addition, if the market capitalization of the Company is in excess of $500 million for at least fifteen consecutive trading days, then Mr. Wolf will be entitled to receive additional restricted stock or a stock option equal to 2% of the then outstanding Common Shares. Also, does not include options to purchase Common Shares that do not vest within 60 days of the date of this filing.

     

     

     

     
     

     

    CUSIP No. 42237K 409                                              13D                                Page 7 of 8 pages

     

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     

    Item 6 is hereby amended and supplemented by adding the following:

     

    Except as otherwise set forth in Amendment No. 6 to this Schedule 13D, there are no contracts, arrangements, understandings or similar relationships existing with respect to the securities of the Company between the Reporting Persons and any other person or entity.

     

    Item 7. Material to be filed as Exhibits.

     

    Item 7 is hereby amended and supplemented by adding the following:

     

    Exhibit 1:   Joint Filing Agreement
         
    Exhibit 2:   Form of Amended and Restated Restricted Stock Agreement (previously filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 15, 2021 (File No. 001-35994)).
         
         
         

     

     
     

     

    CUSIP No. 42237K 409                                              13D                               Page 8 of 8 pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: December 16, 2021

     

        /s/ Jeffrey Wolf
        Jeffrey Wolf

     

        ORION HOLDINGS V, LLC
           
        By: /s/ Jeffrey Wolf
          Jeffrey Wolf
          Managing Member

     

        SEED-ONE HOLDINGS VI, LLC
           
        By: /s/ Jeffrey Wolf
          Jeffrey Wolf
          Managing Member

     

     

     

     
     

     

    Transactions by the Reporting Person During the Past Sixty Days

     

    * As disclosed in this Amendment No. 6 to Schedule 13D, on December 13, 2021, Mr. Wolf was issued options to purchase 393,761 shares of common stock and 246,305 shares of restricted common stock as compensation pursuant to the Company’s equity incentive plan.

     

     

     

     

     

    Get the next $HTBX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HTBX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HTBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Heat Biologics with a new price target

      Cantor Fitzgerald initiated coverage of Heat Biologics with a rating of Overweight and set a new price target of $22.00

      3/3/21 5:02:25 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Heat Biologics

      Cantor Fitzgerald initiated coverage of Heat Biologics with a rating of Overweight

      3/2/21 4:30:37 PM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners reiterated coverage on Heat Biologics with a new price target

      Alliance Global Partners reiterated coverage of Heat Biologics with a rating of Buy and set a new price target of $40.00 from $5.00 previously

      2/9/21 4:14:42 PM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HTBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Wolf Jeffrey Alan

      4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)

      12/9/22 5:03:50 PM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Smith Edward B Iii

      4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)

      12/9/22 5:01:55 PM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Prendergast John K A

      4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)

      12/9/22 5:00:34 PM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HTBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35

      DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA, NightHawk's Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit being held on May 17-19th in Boston. PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells and can be utilized to expand regulator

      5/10/22 8:00:00 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open Today

      DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has completed its name change from Heat Biologics, Inc. to NightHawk Biosciences, Inc. to better reflect the Company's evolution, including expansion of the therapeutic pipeline, vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effective today, May

      5/3/22 7:00:00 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

      DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM® (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack. ANTHIM® will be delivered to Canada's National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni. The goal of this program is to establish a Canadian

      4/27/22 8:00:00 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HTBX
    SEC Filings

    See more
    • Heat Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)

      1/5/23 5:14:27 PM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heat Biologics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)

      12/9/22 5:07:37 PM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Heat Biologics Inc.

      10-Q - NightHawk Biosciences, Inc. (0001476963) (Filer)

      11/14/22 4:27:54 PM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HTBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company

      DURHAM, N.C., March 23, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, announces the appointment of Greg Burel, former Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR) Director of the Strategic National Stockpile (SNS), to the Company's Biothreat Advisory Board and as a senior advisor to the Company. Mr. Burel served as the Director of SNS from March 2007 to January 2020. In this role, Mr. Burel directed the nation's premier medical materiel prepared

      3/23/22 8:30:00 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy

      DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Paul Tebbey, Ph.D. as Senior Vice President of Product Development and Portfolio Strategy. Dr. Tebbey is a pharmaceutical development strategy leader with over 25 years of healthcare and management experience across the biotechnology and pharmaceutical sectors at companies such as Abbvie, Baxter, Centocor/Johnson & Johnson and Wyeth/Pfizer. Dr. Tebbey's research, development and commercial launch experiences include novel monoclonal antibodies

      10/6/21 7:30:00 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor

      DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) --  Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the appointment of Anthony Manning, Ph.D. as Chief Scientific Advisor. Dr. Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics' product portfolio. Dr. Manning brings over three decades of experience in immunology and autoimmune disease research and development. Most recently, Dr. Manning served as Chief Scientific Officer and Head of Research at M

      5/10/21 7:30:00 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HTBX
    Financials

    Live finance-specific insights

    See more
    • Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics

      Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. Nighthawk

      4/20/22 8:00:00 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

      DURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today announced that it is changing the name of the Company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company's evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effec

      4/19/22 11:00:00 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heat Biologics to Provide Corporate Update

      DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will host a conference call on Thursday, September 2nd at 11:00 A.M. Eastern Time to provide an update on the Company's activities. The conference call may be accessed by dialing 844-602-0380 for U.S. callers or +1 862-298-0970 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2768/42602 or on the Company's website at https://ir.heatbio.com/. An audio replay of the call will be available th

      8/30/21 7:30:00 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HTBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Heat Biologics Inc. (Amendment)

      SC 13D/A - NightHawk Biosciences, Inc. (0001476963) (Subject)

      12/30/22 4:06:04 PM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Heat Biologics, Inc. (Amendment)

      SC 13D/A - HEAT BIOLOGICS, INC. (0001476963) (Subject)

      12/16/21 7:52:43 AM ET
      $HTBX
      Biotechnology: Pharmaceutical Preparations
      Health Care